Home

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Recent News

May 24, 2017
– Pharmaceutical formulation of cannabidiol significantly reduced convulsive seizure frequency in children on multiple anti-epileptic drugs with poor seizure control – – First well-controlled clinical study of cannabidiol in Dravet syndrome, a rare, severe type of epilepsy with no FDA-approved treatments –
May 15, 2017
- Dr. Volker Knappertz appointed Chief Medical Officer - - Professor Ben Whalley to join as Head of Discovery Research -
May 09, 2017
- Epidiolex® NDA submission expected mid-year– - New data in Lennox-Gastaut syndrome presented at the American Academy of Neurology - -Conference call today at 4:30 p.m. EST-

Pharmaceutical Development Pipeline

Pharmaceutical Development Pipeline

  • Unpartnered
  • Partnered
  • Pre-Clinic
  • Phase 1
  • Phase 2
  • Phase 3
  • Submit
  • Approved

Epidiolex

Epidiolex
Dravet Syndrome
Completed Phase 3
Epidiolex
Lennox-Gastaut Syndrome
Completed Phase 3
Epidiolex
Tuberous Sclerosis
Phase 3
Epidiolex
Infantile Spasms
Phase 2

CBDV (GWP42006)

GWP42006 (CBDV)
Epilepsy
Phase 2
GWP42006 (CBDV)
Autism Spectrum Disorders
Phase 1

Other

GWP42003 (IV)
Neonatal Hypoxic-ischemic Encephalopathy
Phase 1
GWP42002 / GWP42003
Glioma
Completed Phase 2
GWP42003
Schizophrenia
Completed Phase 2

Sativex (Partnered)

Sativex
Ms Spasticity
Approved